Publications Gastrointestinal Cancer

  • « overview publications


  • Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophago-gastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS.1.2.001

    M. Hejna, M. Raderer, J. Zacherl, A. Ba-Ssalamah, A. Püspök, U. Pluschnig, T. Brodowicz, C. Zielinski

    Anti-Cancer Drugs, 2008, 19:535-539

  • Clinical Benefit and Quality of Life in Patients with advanced pancreatic Cancer receiving Gemcitabine plus Capecitabine versus Capecitabine alone: A randomized multicenter Phase III Clinical Trial - SAKK 44/00 - CECOG/PAN.1.3.001

    J. Bernhard, D. Dietrich, W. Scheithauer, D. Gerber, G. Bodoky, T. Ruhstaller, B. Glimelius, E. Bajetta, J. Schüller, P. Saletti, J. Bauer, A. Figer, B. Pestalozzi, C. Köhne, W. Migrone, S. Stemmer, K. Támas, G. Kornek, D. Koeberle, R. Herrmann

    Journal of Clinical Oncology, 2008, 26: 3695ff

  • Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial

    Herrmann R, Bodoky G, Ruhstaller T, Glimelius B, Bajetta E, Schuller J, Saletti P, Bauer J, Figer A, Pestalozzi B, Kohne CH, Mingrone W, Stemmer SM, Tamas K, Kornek GV, Koeberle D, Cina S, Bernhard J, Dietrich D, Scheithauer W; Swiss Group for Clinical Cancer Research; Central European Cooperative Oncology Group.

    Journal of Clinical Oncology, 2007, 25: 2212-2217.

  • Gemcitabine plus Capecitabine versus Gemcitabine alone in advanced pancreatic cancer. A randomized phase III trial.

    R. Herrmann, G. Bodoky, T. Ruhstaller, B. Glimelius, P. Saletti, E. Bajetta, J. Schueller, J. Bernhard, D. Dietrich, W. Scheithauer.

    Proc.Am.Soc.Clin.Oncol (Abstract No: 4010, Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No. 16S, Part I of II (June 1 Supplement), 2005:4010

  • Phase II study of docetaxel in combination with oxaliplatin in patients with metastatic or locally advanced esophagogastric cancer previously untreated with chemotherapy for advanced disease. Results of the CECOG-Study ESGAS 1.2.001

    M. Hejna, J. Zacherl, A Ba-Ssalamah, A. Püspök, U. Pluschnig, T. Brodowicz, C. Zielinski, M. Raderer

    Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 4527 and Anti Cancer drugs (in press).



For publications of the results of the Consensus Conferenences
see Consensus Statements